Rigel Pharma (RIGL) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $51.29 +4.97%
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $36.84 million versus the consensus estimate of $33.7 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applovin shares surge on strong Q3 results and guidance
- Western Union (WU) Tops Q3 EPS by 8c; offers guidance
- Cadre Holdings (CDRE) Tops Q3 EPS by 9c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
